Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
06/15/2022 | Avidity Biosciences, Inc. | RNA | Grant | Stock Option (Right to Buy) | 22k | $12.03 | $264.7k | | 06/15/2022 |
06/13/2022 | ROCKET PHARMACEUTICALS, INC. | RCKT | Grant | Stock Option (Right to Buy) | 47.7k | $10.77 | $514.2k | | 06/13/2022 |
06/16/2021 | Avidity Biosciences, Inc. | RNA | Grant | Stock Option (Right to Buy) | 15k | $26.09 | $391.4k | | 06/16/2021 |
06/14/2021 | ROCKET PHARMACEUTICALS, INC. | RCKT | Grant | Stock Option (Right to Buy) | 12.2k | $47.25 | $578.2k | | 06/14/2021 |
06/16/2020 | ROCKET PHARMACEUTICALS, INC. | RCKT | Grant | Stock Option (Right to Buy) | 20k | $19.90 | $398k | | 06/16/2020 |
01/28/2019 | ROCKET PHARMACEUTICALS, INC. | RCKT | Grant | Stock Option (Right to Buy) | 30k | $14.56 | $436.8k | | 01/28/2019 |
05/29/2018 | Kiniksa Pharmaceuticals, Ltd. | KNSA | Conversion | Class A Common Shares | 6.4k | $0.00 | $0 | | 05/29/2018 |
05/29/2018 | Kiniksa Pharmaceuticals, Ltd. | KNSA | Conversion | Class B Common Shares | 107k | $0.00 | $0 | | 05/29/2018 |
05/29/2018 | Kiniksa Pharmaceuticals, Ltd. | KNSA | Conversion | Series C Preferred Shares | 6.4k | $0.00 | $0 | | 05/29/2018 |
03/29/2018 | ROCKET PHARMACEUTICALS, INC. | RCKT | Grant | Stock Option (Right to Buy) | 40k | $18.75 | $750k | | 03/29/2018 |
02/09/2018 | Kiniksa Pharmaceuticals, Ltd. | KNSA | Purchase | Series C Preferred Shares | 6.4k | $15.64 | $100k | | 05/29/2018 |
06/20/2017 | ROCKET PHARMACEUTICALS, INC. | RCKT | Grant | Stock Options (Right to Buy) | 45k | $1.80 | $81k | | 06/20/2017 |
06/23/2016 | ROCKET PHARMACEUTICALS, INC. | RCKT | Grant | Stock Options (Right to Buy) | 12k | $7.61 | $91.3k | | 06/23/2016 |
01/11/2016 | ROCKET PHARMACEUTICALS, INC. | RCKT | Grant | Stock Options (Right to Buy) | 24k | $8.89 | $213.4k | | 01/11/2016 |
02/17/2015 | SYNAGEVA BIOPHARMA CORP | GEVA | Exercise | Stock Option (Right to Buy) | 29.1k | $40.74 | $1.2M | | 02/17/2015 |
02/17/2015 | SYNAGEVA BIOPHARMA CORP | GEVA | Exercise | Stock Option (Right to Buy) | 13.2k | $1.70 | $22.5k | | 02/17/2015 |
02/17/2015 | SYNAGEVA BIOPHARMA CORP | GEVA | Sale | Common Stock | 9k | $98.85 | $888.6k | | 02/17/2015 |
02/17/2015 | SYNAGEVA BIOPHARMA CORP | GEVA | Sale | Common Stock | 1.8k | $101.69 | $187.3k | | 02/17/2015 |
02/17/2015 | SYNAGEVA BIOPHARMA CORP | GEVA | Sale | Common Stock | 16.7k | $100.74 | $1.7M | | 02/17/2015 |
02/17/2015 | SYNAGEVA BIOPHARMA CORP | GEVA | Sale | Common Stock | 14.8k | $99.97 | $1.5M | | 02/17/2015 |
10/30/2014 | SYNAGEVA BIOPHARMA CORP | GEVA | Sale | Common Stock | 22.9k | $80.11 | $1.8M | | 10/28/2014 |
10/30/2014 | SYNAGEVA BIOPHARMA CORP | GEVA | Exercise | Stock Option (Right to Buy) | 7.9k | $23.00 | $180.6k | | 10/28/2014 |
10/30/2014 | SYNAGEVA BIOPHARMA CORP | GEVA | Exercise | Stock Option (Right to Buy) | 15k | $1.70 | $25.6k | | 10/28/2014 |
10/28/2014 | SYNAGEVA BIOPHARMA CORP | GEVA | Exercise | Stock Option (Right to Buy) | 1000 | $23.00 | $23k | | 10/28/2014 |
10/28/2014 | SYNAGEVA BIOPHARMA CORP | GEVA | Exercise | Stock Option (Right to Buy) | 1.5k | $1.70 | $2.6k | | 10/28/2014 |
10/28/2014 | SYNAGEVA BIOPHARMA CORP | GEVA | Sale | Common Stock | 1000 | $80.00 | $80k | | 10/28/2014 |
10/28/2014 | SYNAGEVA BIOPHARMA CORP | GEVA | Sale | Common Stock | 1.5k | $80.00 | $120k | | 10/28/2014 |
06/04/2014 | SYNAGEVA BIOPHARMA CORP | GEVA | Grant | Stock Option (Right to Buy) | 40k | $80.35 | $3.2M | | 06/04/2014 |
05/16/2014 | SYNAGEVA BIOPHARMA CORP | GEVA | Exercise | Stock Option (Right to Buy) | 9.9k | $1.70 | $16.9k | | 05/16/2014 |
05/16/2014 | SYNAGEVA BIOPHARMA CORP | GEVA | Sale | Common Stock | 200 | $83.46 | $16.7k | | 05/16/2014 |
05/16/2014 | SYNAGEVA BIOPHARMA CORP | GEVA | Sale | Common Stock | 1.6k | $82.71 | $131.6k | | 05/16/2014 |
05/16/2014 | SYNAGEVA BIOPHARMA CORP | GEVA | Sale | Common Stock | 8.1k | $81.75 | $665.1k | | 05/16/2014 |
02/18/2014 | SYNAGEVA BIOPHARMA CORP | GEVA | Sale | Common Stock | 3.2k | $102.18 | $327.7k | | 02/18/2014 |
02/18/2014 | SYNAGEVA BIOPHARMA CORP | GEVA | Sale | Common Stock | 1.7k | $103.05 | $179.8k | | 02/18/2014 |
02/18/2014 | SYNAGEVA BIOPHARMA CORP | GEVA | Sale | Common Stock | 894 | $104.22 | $93.2k | | 02/18/2014 |
|